Scilex Files $500 M Shelf Registration to Fund Non‑Opioid Pain Innovation
Scilex Holding files a $500 M shelf registration to fund non‑opioid pain therapies, boosting R&D, commercialization and growth prospects.
3 minutes to read
Scilex Holding Co
Scilex Holding: Rising from Volatility to a Promise in Non‑Opioid Pain Solutions
Scilex Holding Company’s non‑opioid pain solutions face volatile stock moves, low PE, yet show resilience. Discover its financial outlook and market potential.
3 minutes to read
Scilex Holdings Invests $20M in Quantum Scan to Expand Non‑Opioid Pain & Diagnosis Markets
Scilex Holding Company boosts its biopharma reach with a $20 M Quantum Scan investment, expanding non‑opioid pain solutions amid volatile biotech markets.
2 minutes to read
Scilex Faces Volatility: Investor Concerns Over Negative P/E, P/B Ratios
Scilex Holding’s stock swings reveal deep financial woes, but its focus on non‑opioid pain meds could spark a rebound – investors watch closely.
2 minutes to read
Scilex Strengthens IP & Boosts Shareholder Value Amid Market Volatility
Scilex Holding Co. boosts IP defenses with Kasowitz LLP and cuts share dilution via a $27 M options buyback, positioning itself for growth in the non‑opioid pain market.
3 minutes to read
Scilex Holding Co. Announces CEO Resignation Amid Strategic Merger and Funding for Non-Opioid Pain Drug
Scilex Holding Company is undergoing leadership changes, including the resignation of CEO Jaisim Shah, as the company shifts its focus towards the merger of its subsidiary Semnur Pharmaceuticals with Denali Capital Acquisition Corp.
2 minutes to read